Introduction {#S1}
============

In an official judo competition, athletes perform several matches with short recovery periods between them (approximately 10 to 15 min), which may induce muscle fatigue and damage, reducing athlete performance over the competition. A previous study found decrements of up to ∼8--12% in isometric handgrip strength after the second match during an official judo competition ([@B42]). In simulated judo matches, a 3.6% decrease was observed in countermovement jump (CMJ) performance after the second match and increased values of serum creatine kinase (CK) and lactate dehydrogenase (LDH) after the third match ([@B21]), supporting that the physical effort expended during judo matches induced fatigue and muscle damage. Fatigue and muscle damage can also be caused by traditional training sessions. It is known that a 2-h judo-specific training session provokes increases in biochemical markers of muscle damage (CK and LDH) and in acute immune response ([@B59]). In addition, [@B20] reported increases in CK, LDH, and muscle soreness, as well as a decrease in lower limb performance (i.e., CMJ) 48 h after a traditional judo training session. However, upper limb performance recovered faster, returning to baseline values after 24 h, which indicates that lower limbs are more affected during judo practice.

High-intensity exercises, especially those involving short recovery time and high eccentric-concentric contractions (e.g., stretch-shortening cycle -- SSC) induce immediate and prolonged reductions in muscle function due to fatigue and/or muscle damage ([@B53]; [@B33]). The optimization of SSC seems to be a specific characteristic of judo training, since a previous study found better utilization of SSC in advanced judo athletes and higher CMJ height compared to untrained males ([@B62]). Moreover, CMJ performance is positively related to the number of throws in a judo-specific test ([@B18]) and technical-tactical parameters in official judo competitions ([@B41]). Since the efforts involving SSC generate high mechanical load, producing great stress in muscle structures ([@B53]; [@B33]), strategies that attenuate exercise-induced fatigue would therefore maintain physical performance in combat and training sessions, allowing execution of repeated movement with greater intensities for longer periods. Moreover, reducing fatigue and muscle damage would allow faster recovery intra or between training sessions and between the combat sequences, thus acutely maintaining or chronically increasing physical performance and diminishing the risks of injury ([@B34]).

Evidence has shown that photobiomodulation therapy (PBMT) prior to exercise can be used as a tool to attenuate fatigue in humans following strength and aerobic exercises ([@B6]; [@B48]; [@B25]; [@B56]; [@B16], [@B17]; [@B45], [@B46]; [@B60]). Moreover, it has recently been reported that PBMT reduced fatigue and facilitated faster recovery in another combat sport (i.e., Brazilian jiu-jitsu) ([@B3]; [@B26]). In summary, PBMT-related muscle fatigue attenuation mechanisms involve factors such as absorption of photons by chromophores and subsequent transduction of light energy into chemical energy within the cytoplasmic organelles ([@B54]). In addition, increases in permeability and consequent transport by the cytoplasmic membrane have been observed ([@B39]), improving activity of oxidative enzymes associated with the IV complex (Oxidase C Cytochrome) ([@B57]; [@B35]), and increased mitochondrial size and number ([@B52]). Considering muscle damage symptoms, several human trials have reported the benefits of applying PBMT prior to exercise to attenuate damage markers, such as delayed onset muscle soreness, strength impairments, and/or echo intensity increases ([@B4]; [@B2]; [@B22]; [@B29]). PBMT acts by reducing fatigue, as abovementioned, leading to improved ATP production and delaying cellular acidosis and its negative effect on cell metabolism ([@B30]; [@B36]). A reduction in reactive oxygen species and oxidative stress have also been observed, resulting in an anti-inflammatory action, which is related to muscle damage ([@B49]).

Athletes require attenuation of fatigue to maintain physical performance for longer periods, supporting high loads during training, high-intensity actions during competition, and reducing the risks of injuries ([@B1]; [@B58]). Moreover, they require attenuated muscle damage following training sessions and matches to accelerate recovery, which may result in maintenance of physical performance for the following sessions/matches ([@B53]; [@B33]; [@B34]). Therefore, PBMT may be an effective tool to attenuate judo athletes' exercise-related fatigue and muscle damage in high-intensity efforts, as observed in judo matches and training sessions, maintaining performance and accelerating muscular recovery. Distinct sports can elicit different types of training-related physiological adaptations that are associated with their specificity, which could affect the athletes' responses to PBMT. Although PBMT has been demonstrated to be effective for several sports and exercise modalities ([@B6]; [@B48]; [@B25]; [@B56]; [@B16], [@B17]; [@B45], [@B46]; [@B60]), no studies have investigated their effects in judo athletes. Thus, the purpose of this study was to investigate the effects of pre-exercise PBMT on fatigue and muscle damage markers (i.e., CMJ performance, muscle echo intensity, and soreness) up to 48 h after exercise in judo athletes. The initial hypothesis was that PBMT would attenuate fatigue-related reductions of CMJ performance, and diminish the increases in echo intensity and muscle soreness following exercise.

Materials and Methods {#S2}
=====================

Participants {#S2.SS1}
------------

Athlete selection was performed in the east of Santa Catarina state, Brazil. The following inclusion criteria were adopted: (1) more than 6 years of judo practice; (2) graduation of purple, brown, or black belt athletes; (3) not be in a rapid weight loss or competition period; and (4) not presenting any musculoskeletal injury in the previous 2 years that could limit neuromuscular testing. Athletes were excluded according to the following criteria: (1) alcohol or medication intake during the data collection period; (2) not properly executing the neuromuscular assessments; (3) not reporting to the laboratory at the correct time of day; and (4) feeling any exacerbation (i.e., injury-related discomfort during the neuromuscular assessment).

Twenty-four judo athletes volunteered, of which sixteen completed all the study procedures. These comprised four purple belts, five brown belts, and seven black belts with the following characteristics: 23.1 ± 3.8 years, 77.9 ± 14.9 kg, 173.1 ± 8.9 cm, 17.5 ± 7.3% of body fat, and time of practice of 12.9 ± 5.0 years. All athletes had already participated in several national and state tournaments and were engaged in regular training (technical--tactical, aerobic, and resistance training) 3--4 times a week. The selected athletes were in the preparatory phase and therefore the athletes were not in a period of rapid weight loss. In addition, the participants were instructed not to intake alcohol or medication (e.g., anti-inflammatory or pain relievers) for at least 48 h before and during the evaluations, and to maintain their normal diet. Eight athletes were excluded due to previous lower limb injury (*n* = 3), participation in official competitions (*n* = 3), or a weight loss period (*n* = 2) during the data collection. Before the assessments, all subjects were informed about the procedures and signed an informed consent form. Ethical approval was obtained from the local Human Research Ethics Committee (30495314000005347), in accordance with the Declaration of Helsinki.

Experimental Design {#S2.SS2}
-------------------

This study was a randomized, triple-blinded, and placebo-controlled trial. After recruitment, 2 weeks before the experimental protocol, participants were familiarized with the CMJ (3 times/week) during their judo training sessions. The familiarization consisted of five bilateral and five unilateral (each leg) CMJs per day. Thereafter, participants were requested to avoid any lower limb exercises for 48 h before and during the 3 days of the experimental protocol ([Figure 1](#F1){ref-type="fig"}).

![Experimental design of visits 1, 2, and 3.](fphys-10-00811-g001){#F1}

In the first laboratory visit, body mass, height, and anthropometric measurements were recorded. Baseline measurements began with ultrasonography assessments. Thereafter, participants responded to a visual analog scale of muscle soreness and performed the warm-up and unilateral CMJ records. After baseline assessments, simple randomization was used to determine which lower limb would be treated with PBMT or placebo, to reduce any possible influence of limb preference on muscle fatigue and damage results. Eight participants received PBMT in the preferred limb (self-reported by each athlete) and eight in the non-preferred limb, whereas, the contralateral limb received placebo. In sequence, the plyometric protocol was performed to induce fatigue and muscle damage. After the fifth and after the tenth sets, one unilateral CMJ was performed for each leg. After each set, the rate of perceived exertion (RPE) was recorded, and after the complete protocol, the visual analog scale for fatigue and muscle soreness was applied.

The second and third laboratory visits took place 24 h (±2) and 48 h (±2) after the first visit, respectively. The visual analog scale of muscle soreness, ultrasonography, and CMJ assessments were performed exactly as described on the first visit, in the baseline assessments, before the PBMT application.

Muscle Fatigue and Damage Protocol {#S2.SS3}
----------------------------------

To induce fatigue and muscle damage an SSC protocol was adopted, consisting of 10 sets of 10 repetitions of consecutive maximal bilateral CMJs (1-min rest between sets) on a piezoelectric force platform (model 9290AD; Kistler, Quattro Jump, Winterthur, Switzerland), which measures vertical ground reaction force at a sampling rate of 500 Hz. This protocol was recently adopted to investigate PBMT effects on muscle damage ([@B29]) and a similar protocol (30-s rest between sets) was used to induce fatigue. Participants received standardized instructions, verbal guidance, and encouragement during the protocol and the same researcher controlled all protocols. Participants were required to bend their knees and hips until approximately 90° of flexion in every CMJ. Fatigue was observed during the protocol due to a reduction of −9.5 ± 6.6% in mean power output and a rate of perceived exertion (0--10) of 6.4 ± 2.2.

Countermovement Jump Assessment {#S2.SS4}
-------------------------------

Neuromuscular status, assessed through CMJ (usually performed bilaterally), has been used as a reliable non-invasive method to assess fatigue and muscle damage effects on performance ([@B61]; [@B12]). In addition, the bilateral CMJ was correlated with technical-tactical variables (e.g., number of attacks, effectiveness, and effective combat time) obtained in official judo matches and judo-specific test performance ([@B41]).

The CMJ was assessed using a strain gauge force platform (AMTI model OR6-6, Watertown, MA, United States), which measures vertical ground reaction force at a sampling rate of 1000 Hz. For the baseline, 24 h, and 48 h measurements participants performed a warm-up, consisting of 5 min on a cycle ergometer, 10 hops, five submaximal bilateral and three submaximal unilateral (each leg) CMJs (30-s rest between jumps). Two minutes later, five consecutive maximal CMJs were performed 30 s before the unilateral CMJs to ensure potentiated performance. To avoid exacerbated recovery, only one unilateral CMJ for each leg was recorded 30 s after the fifth and tenth sets of the plyometric protocol for fatigue monitoring. CMJs always began with the preferred limb, since PBMT was randomized. Half of the participants began with the PBMT treated limb and the other half started with the placebo treated limb.

For a proper technique, the participants started from a static standing on one foot position and were instructed to perform a countermovement (descent phase), followed by a rapid and vigorous extension of the lower limb joints (ascent phase) unilaterally. Their hands remained on their hips and they were instructed to jump as high as possible. Participants were allowed to land with both limbs to avoid exacerbated force on joints of a single limb landing. CMJ impulse ([@B38]), peak power output, peak velocity, and peak force in the concentric phase of the jump were used for analysis ([@B13]).

Echo-Intensity {#S2.SS5}
--------------

Muscular echo intensity, assessed through ultrasonography images, has been used as a reliable non-invasive method to assess the muscle damage level in humans ([@B8]; [@B7]). Echo intensity of *rectus femoris* and *vastus lateralis* muscles was assessed using ultrasonography equipment (Logiq S7, GE Healthcare, Milwaukee, WI, United States) along with a linear array probe (50 mm, 5--15 MHz, ML6-15) from the same manufacturer, coated with a water-soluble transmission gel to provide acoustic contact without depressing the dermal surface.

Prior to each assessment, participants remained in the supine position with knees and hips in neutral position and rested for 10 min in order to allow fluid shifts to occur ([@B50]). Three transversal images from the *rectus femoris* and *vastus lateralis* were obtained at 50% of the distance between the lateral condyle of the femur and the great trochanter ([@B43]). To ensure that all measurements were performed at the same site, on the first day a waterproof pen was used to mark the exact site where the subsequent assessments should be carried out. All measurements were performed by the same trained researcher.

Posteriorly, all images were analyzed with ImageJ software (National Institutes of Health, United States). A square with an area of 1 cm^2^ was positioned at the mid-point of the *rectus femoris* and *vastus lateralis* muscles for the echogenicity calculation (echo intensity). Echo intensity of each muscle was determined using the gray-scale analyses function and expressed in arbitrary units as a value between 0 (black) and 255 (white). The mean value between the three images from each day was used for analysis.

Rate of Perceived Exertion, Rate of Perceived Fatigue, and Muscle Soreness Assessments {#S2.SS6}
--------------------------------------------------------------------------------------

A visual analog scale was used to identify the occurrence of muscle soreness related to delayed onset muscle soreness at baseline, immediately after, and 24 and 48 h after the end of the protocol. The scale ranged from 0 to 10, in which 0 was considered the absence of soreness and 10 the presence of unbearable soreness. Participants reported muscle soreness in specific muscle groups of the lower body (knee extensors, knee flexors, and plantar flexors), by indicating the area on an anatomical diagram ([@B19]). The delayed onset muscle soreness after a high intensity effort is considered a marker of muscle damage ([@B34]).

Rate of perceived exertion was recorded on a scale ranging from 0--10 (0 = no exertion at all and 10 = maximal exertion) after every set of the plyometric protocol. In addition, after the complete protocol participants indicated their perception of fatigue during the exercise for each leg using visual analog scales ([@B44]), which consisted of a single 100 mm horizontal line with a headline statement at the top. The extreme left of the line indicated no fatigue, and to the extreme right, the statement indicated very fatiguing. Participants were asked to indicate their perception of fatigue with a single vertical line for each leg.

Photobiomodulation/Placebo Treatment {#S2.SS7}
------------------------------------

Photobiomodulation therapy or placebo treatments were applied using a Chattanooga Intelect Mobile Laser 2779 system (Chattanooga Group, Guildford, Surrey, United Kingdom). PBMT or placebo were applied on 15 sites on each lower limb: eight sites on the quadriceps (three sites on *vastus lateralis*, three sites on *rectus femoris*, and two sites on *vastus medialis*), four sites on the hamstrings (two on *semitendinosus* and two on *semimembranosus*), two sites on the *gastrocnemius* (one on lateralis and one on mediallis areas), and one site on the *soleus*. Only the researcher responsible for the PBMT application was aware of the treatment. The other researchers that performed the assessments and participants were blinded to the respective treatments.

The PBMT/placebo treatment lasted about 8 min. While one lower limb received the PBMT, the other received the placebo simultaneously with two probes held stationary with skin contact at a 90° angle with light skin pressure. The placebo probe remained turned off throughout the treatment time. The PBMT general characteristics comprise cluster size = 30.2 cm^2^, number of sites = 15, treatment time per site = 32 s, dose per site = 30 J, and total dose = 450 J (Quadriceps = 240 J, Hamstrings = 120 J, and Gastrocnemius = 60 J). Recently a meta-analysis reported effective doses of 60--300 J for large and 20--60 J for small muscle groups ([@B60]). Additional PBMT parameters are described in [Table 1](#T1){ref-type="table"}.

###### 

Photobiomodulation therapy parameters.

  **Parameters**             **LASERs (850 nm)**   **LEDs (670 nm)**   **LEDs (880 nm)**   **LEDs (950 nm)**
  -------------------------- --------------------- ------------------- ------------------- -------------------
  Number of diodes           5                     12                  8                   8
  Power output (mW)          100                   10                  25                  15
  Spot size (cm^2^)          0.06                  1.92                1.28                1.28
  Power density (mW/cm^2^)   1666.6                5.2                 1.93                11.71
  Frequency                  Continuous            Continuous          Continuous          Continuous
  Dose (J)                   3.2                   0.3                 0.8                 0.5

Statistical Analysis {#S2.SS8}
--------------------

All statistical analyses were performed by a blinded researcher, who did not know which treatment groups "1" and "2" received. After analyses, and table and figure production, the groups were revealed and the respective labeling was included. The sample size was calculated (G^\*^POWER software, version 3.1.9.2., Universität Kiel, Germany) for ANOVA repeated measures, within-between interaction (effect size = 0.25, α = 0.05, β = 0.80, number of groups = 2, number of measurements = 3, correlation among repeated measures = 0.5, non-sphericity correction = 1). A minimum of 14 participants per group was determined.

The intraclass correlation coefficient (ICC) and typical error as coefficient of variation (CV) were calculated for the three unilateral CMJ trials and for the echo intensity obtained from the three images for each muscle at baseline to verify their reliability ([@B31]). The normality of the distribution and homoscedasticity for outcome measures were tested using the Shapiro--Wilk, and Mauchly and Levene criteria, respectively. The Student *t*-test for independent samples was used to compare baseline of the preferred and non-preferred limbs for CMJ variables and echo intensity, as well as to compare the post-SSC protocol, VAS (fatigue), and the fatigue index between PBMT and placebo for CMJ variables. Two-way ANOVA repeated measures was used to analyze: (a) treatment (PBMT × placebo) × time (baseline, middle protocol, post-protocol, 24 h, and 48 h) interaction for unilateral CMJ variables; (b) treatment (PBMT × placebo) × time (baseline, post-protocol, 24 h, and 48 h) interaction for muscle soreness; and (c) treatment (PBMT × placebo) × time (baseline, 24 h, and 48 h) interaction for echo intensity. When Mauchly's test of sphericity was significant and the Greenhouse-Geisser level of violation was \>0.75, degrees of freedom were corrected using the Huynh-Feldt adjustment, and when violation was \<0.75, the Greenhouse-Geisser correction was used. When a significant *F*-value was achieved, Bonferroni's *post hoc* tests were used to determine the pair-wise differences between the different time points and between groups. An alpha level of 5% was used in all statistical analyses. Effect size was used to quantify the meaningfulness of any differences and was calculated using partial eta squared (η~p~^2^; trivial, \<0.1; small, 0.1--0.29; moderate, 0.3--0.49; or large, ≥0.5) ([@B32]). ANOVA degrees of freedom are reported as df.

Results {#S3}
=======

Baseline Characteristics {#S3.SS1}
------------------------

Similar values were observed for preferred and non-preferred limb echo intensity (*rectus femoris* and *vastus lateralis*), and CMJ performance (peak force, peak velocity, peak power output, and impulse) ([Table 2](#T2){ref-type="table"}) at the baseline condition. In addition, the same was observed when comparing baseline values between PBMT or placebo treated limbs for all the abovementioned variables ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}), showing homogeneity of data for both legs and both conditions at baseline.

###### 

Mean and standard deviation values (95% confidence interval upper and lower limits) for echo intensity and countermovement jump characteristics at the baseline.

  **Variables**    **Preferred limb**                       **Non-preferred limb**                   ***p-*value**
  ---------------- ---------------------------------------- ---------------------------------------- ---------------
  EI~RF~ (a.u.)    $124.1 \pm {14.1{({116.6 - 131.6})}}$    $125.9 \pm {10.9{({120.1 - 131.7})}}$    0.685
  EI~VL~ (a.u.)    $118.4 \pm {12.6{({111.7 - 125.2})}}$    $109.2 \pm {14.9{({101.3 - 117.2})}}$    0.069
  CMJ~PF~ (N)      ${1,438} \pm {239{(1,{305 - 1},570)}}$   ${1,415} \pm {222{(1,{291 - 1},538)}}$   0.793
  CMJ~PV~ (m/s)    $2.18 \pm {0.25{({2.05 - 2.32})}}$       $2.09 \pm {0.17{({2.00 - 2.19})}}$       0.253
  CMJ~PPO~ (W)     ${2,547} \pm {409{(2,{320 - 2},773)}}$   ${2,426} \pm {379{(2,{216 - 2},636)}}$   0.460
  CMJ~IMP~ (N⋅s)   $140 \pm {24{({126 - 153})}}$            $136 \pm {23{({123 - 149})}}$            0.659

EI, echo intensity; RF,

rectus femoris

; VL,

vastus lateralis

; CMJ, countermovement jump; PPO, peak power output; MPO, mean power output; PF, peak force; PV, peak velocity; IMP, impulse.

![Countermovement jump impulse **(A)**, peak power output **(B)**, peak velocity **(C)**, and peak force **(D)** means and standard deviation at baseline, fifth set, immediately post, and after 24 and 48 h for PBMT (red lines) and placebo (gray lines). ^\*^Different compared to baseline; \#Different compared to 24 and 48 h.](fphys-10-00811-g002){#F2}

Countermovement Jump {#S3.SS2}
--------------------

There were no treatment-time interactions for CMJ impulse (df = 2.905; *F* = 0.690; *p* = 0.556; η~p~^2^ = 0.024), peak power output (df = 2.206; *F* = 0.279; *p* = 0.779; η~p~^2^ = 0.009), peak velocity (df = 2.108; *F* = 0.185; *p* = 0.842; η~p~^2^ = 0.006), and peak force (df = 1.631; *F* = 0.088; *p* = 0.880; η~p~^2^ = 0.003). While a moderate time effect was observed for impulse (df = 2.905; *F* = 15.009; *p* \< 0.001; η~p~^2^ = 0.349) and peak power output (df = 2.206; *F* = 21.348; *p* \< 0.001; η~p~^2^ = 0.416), and small time effect for peak velocity (df = 2.108; *F* = 8.456; *p* \< 0.001; η~p~^2^ = 0.220) and peak force (df = 2.631; *F* = 11.497; *p* \< 0.001; η~p~^2^ = 0.277).

Countermovement jump impulse reduced after the fifth set (*p* \< 0.001) and at the end of the SSC protocol (immediately post, *p* \< 0.001). Thereafter, it increased after 24 and 48 h compared to post (*p* \< 0.014), but remained lower than baseline (*p* \< 0.05) ([Figure 2A](#F2){ref-type="fig"}). CMJ peak power output, peak velocity, and peak force reduced after the fifth set (*p* \< 0.001) and at the end of the protocol (immediately post, *p* \< 0.001), however, increased after 24 and 48 h (*p* \< 0.006), returning to baseline values (*p* \> 0.430) ([Figures 2B--D](#F2){ref-type="fig"}, respectively). In addition, the fatigue index was similar between PBMT and placebo for CMJ impulse (*p* = 0.788), peak power output (*p* = 0.533), peak velocity (*p* = 0.318), and peak force (*p* = 0.560).

Echo Intensity {#S3.SS3}
--------------

There was no treatment-time interaction for echo intensity for either the *rectus femoris* or *vastus lateralis* (df = 2; *F* = 1.368; *p* = 0.262; η~p~^2^ = 0.044; and df = 1.947; *F* = 0.877; *p* = 0.419; η~p~^2^ = 0.028; respectively), while a large time effect was observed for both (df = 2; *F* = 96.911; *p* \< 0.001; η~p~^2^ = 0.764; and df = 1.947; *F* = 49.155; *p* \< 0.001; η~p~^2^ = 0.621; respectively). *Rectus femoris* and *vastus lateralis* echo intensity increased after 24 h (*p* \< 0.001) and 48 h (*p* \< 0.001), whereas 24 h was similar to 48 h (*p* \> 0.327) ([Figures 3A,B](#F3){ref-type="fig"}, respectively).

![Mean and standard deviation for *Rectus femoris* **(A)** and *Vastus lateralis* **(B)** echo intensity at baseline, and after 24 and 48 h, for PBMT (red lines) and placebo (gray lines). ^\*^Different compared to baseline.](fphys-10-00811-g003){#F3}

Perception of Fatigue and Muscle Soreness {#S3.SS4}
-----------------------------------------

There was no treatment-time interaction for quadriceps muscle soreness (df = 3; *F* = 0.046; *p* = 0.987; η~p~^2^ = 0.002) while a large time effect was detected (df = 3; *F* = 44.515; *p* \< 0.001; η~p~^2^ = 0.597). Muscle soreness increased after the protocol (immediately post, *p* \< 0.001) and increased again after 24 h (*p* \< 0.001) and remained large after 48 h (*p* \< 0.011) ([Figure 4](#F4){ref-type="fig"}).

![Quadriceps muscle soreness means and standard deviation at baseline, immediately post, and after 24 and 48 h for PBMT (red lines) and placebo (gray lines). ^\*^Different compared to baseline; \#Different compared to post.](fphys-10-00811-g004){#F4}

There was no difference (*p* = 0.532) in the visual analog scale for perception of fatigue between the placebo (62.0 ± 21.4, 95% CI: 50.7--73.4) and PBMT (57.4 ± 20.1, 95% CI: 46.7--68.1).

Data Reliability {#S3.SS5}
----------------

Reliability ranged from extremely high (\>0.99) to high (\>0.75 and \<0.90) for the repeated measures of echo intensity and CMJ variables at baseline ([Table 3](#T3){ref-type="table"}).

###### 

Baseline data reliability and typical error (95% confidence interval upper and lower limits).

              **Preferred limb**     **Non-preferred limb**                          
  ----------- ---------------------- ------------------------ ---------------------- -------------------
  EI~RF~      0.993 (0.985--0.997)   1.04 (0.84--1.45)        0.986 (0.969--0.994)   1.10 (0.88--1.53)
  EI~VL~      0.996 (0.990--0.998)   0.80 (0.64--1.10)        0.998 (0.996--0.999)   0.67 (0.54--0.93)
  CMJ~PF~     0.949 (0.888--0.979)   4.83 (3.87--6.77)        0.978 (0.951--0.991)   2.91 (2.33--4.06)
  CMJ~PVEL~   0.786 (0.581--0.906)   5.69 (4.55--7.98)        0.916 (0.820--0.965)   2.77 (2.22--3.86)
  CMJ~PPO~    0.923 (0.834--0.968)   6.14 (4.90--8.61)        0.976 (0.947--0.990)   3.14 (2.51--4.38)
  CMJ~IMP~    0.905 (0.790--0.962)   6.52 (5.22--9.51)        0.957 (0.900--0.983)   4.24 (3.40--6.15)

EI, echo intensity; RF,

rectus femoris

; VL,

vastus lateralis

; CMJ, countermovement jump; PPO, peak power output; MPO, mean power output; PF, peak force; PV, peak velocity; IMP, impulse; ICC, intra-class correlation coefficient; CV, typical error as % of coefficient of variation.

Discussion {#S4}
==========

This was the first study to investigate the effects of PBMT on lower limb fatigue and muscle damage of judo athletes. Our initial hypotheses supposed that PBMT applied before exercise would be effective to attenuate fatigue-related reductions in CMJ performance, and thereafter reduce muscle damage symptoms after an SSC protocol. However, our main findings did not support any of the initial hypotheses, suggesting that PBMT was not effective to reduce fatigue and muscle damage in the lower limbs of judo athletes. These results counteract the findings observed in previous studies with non-athlete populations and different exercise modalities that will be described in the discussion.

The SSC protocol adopted in the present study successfully induced fatigue in lower limb muscles, as evidenced by decreased CMJ impulse, peak power, peak velocity, and peak force performance, and higher perception of fatigue. In summary, muscular fatigue can occur through ATP breakdown and accumulation of fatiguing substances (e.g., H^+^, Na^1+^, K^1+^, Ca^2+^ ions) without enough recovery time for their resynthesizes and removal (respectively) between exercise bouts, reducing contraction performance. It was expected that PBMT would attenuate fatigue through absorption of photons by chromophores and subsequent transduction of light energy into chemical energy within the cytoplasmic organelles ([@B54]); increasing permeability and consequent transport by the cytoplasmic membrane ([@B39]), activity of oxidative enzymes associated with the IV complex (Oxidase C Cytochrome) ([@B57]; [@B35]), and mitochondrial size and number ([@B52]). Moreover, the PBMT can increase microcirculation in a nitric oxide synthase--dependent mechanism, increasing the ATP/adenosine diphosphate (ADP) ratio and local arterial blood flow ([@B47]). However, both PBMT and placebo treated limbs presented a similar decay through the SSC protocol, which indicates that PBMT had no positive effect to attenuate fatigue.

Our results are in disagreement with previous studies in which PBMT reduced fatigue following high intensity neuromuscular exercise. We could hypothesize that the observed differences may be due to the investigated population since some studies adopted non-athlete participants, which would explain the opposed results ([@B15]; [@B55], [@B56]). However, other studies observed positive effects of PBMT in competitive athletes (e.g., Brazilian Jiu-Jitsu, volleyball, soccer, and cycling) ([@B24]; [@B51]; [@B3]; [@B26]; [@B46]). Two studies that investigated PBMT effects in Brazilian Jiu-Jitsu athletes reported reduced upper limb fatigue. These positive effects were observed during an isometric elbow flexion ([@B26]) or hand-grip strength ([@B3]), which indicates that contraction mode, or the assessed limbs may be differently affected by PBMT and could potentially explain the disagreement with our study. For example, some studies adopted isokinetic dynamic contractions for knee extensors/flexors ([@B5]; [@B14]; [@B56]) or plantar flexors ([@B15]), while others investigated isometric contractions ([@B55]; [@B26]). Isometric or isokinetic tests allow control of the angular velocity (e.g., 0--180°/s) and involve a single joint, differently from judo lower limb technique movement, which involves multi-joint explosive SSC contractions ([@B27]). In addition, CMJ and maximum voluntary isometric contraction have demonstrated dissociated time courses of recovery and are possibly mediated by different mechanisms ([@B37]). The importance of SSC performance is evidenced by the relationship of CMJ performance with technical-tactical and specific test performance of judo athletes ([@B41]). Thus, during competition combats or training sessions, muscle fatigue negatively affects judo athletic performance, and the adopted PBMT parameters seem to provide no benefit to attenuate these reductions.

Following a fatiguing high intensity exercise involving SSC, the presence of a great magnitude of muscle damage is expected, mainly due to the presence of eccentric actions ([@B53]; [@B33]). The SSC protocol was effective in inducing muscle damage, as evidenced by decreased CMJ impulse, as well as increased *rectus femoris* and *vastus lateralis* echo intensity, and muscle soreness after 24 and 48 h. During exercises involving SSC, mechanical damage to muscular structures leads to disorganization of the Z-line, T-tubules, sarcoplasmic membrane and reticulum, myofibrils, and cytoskeletal. In the subsequent hours, alteration in Ca^2+^ homeostasis is observed, as well as induced inhibition of mitochondrial function, adenosine triphosphate depletion, inflammatory response, and proteolytic enzyme activation, increasing damage to muscle tissue ([@B11]; [@B28]; [@B34]). Attenuation in muscle damage was expected following the SSC protocol due to lower fatigue ([@B30]; [@B36]), which was not observed (as abovementioned). In addition, lower muscle damage was also expected due to a possible reduction in reactive oxygen species and oxidative stress, which result in an anti-inflammatory action, related to muscle damage ([@B49]).

The presence of muscle damage can decrease contraction performance and consequently reduce force and velocity of contraction ([@B34]), as observed for CMJ impulse. This variable has a large correlation (*r*^2^ = 0.92) with jump height compared to peak power output (*r*^2^ = 0.45) and may better represent athletic performance ([@B38]; [@B40]). The similar decay in CMJ impulse, without differences between treatments 24 and 48 h after the SSC protocol, is a first indicative of the absence of a PBMT effect. Consequently, it is possible to suggest that PBMT cannot attenuate muscular function and, consequently, physical, technical, and tactical performance reductions following training sessions or combats in judo athletes. Our results are in agreement with a previous study that induced muscle damage with an equal SSC protocol, but assessed neuromuscular function with a knee extensor maximum voluntary isometric contraction in non-athletes ([@B29]). Conversely, other studies that induced muscle damage in knee extensors through isokinetic eccentric contraction and assessed muscular performance with maximum voluntary isometric contraction reported positive effects for muscle recovery when PBMT was applied ([@B4]; [@B2]). Our findings cannot provide information to state if the type of exercise used for inducing muscle damage (plyometric vs. isokinetic vs. constant load), the investigated population (athletes and non-athletes), the study design (crossover vs. paired groups), or the different PBMT parameters are responsible for these controversial results.

Echo intensity accessed by ultrasonography presented similar behavior regarding muscle damage. It is suggested that increases in ultrasound echogenicity (i.e., echo intensity) is due to increments in the interstitial space between fibers as a result of connective tissue damage and inflammation, as well as muscle swelling or increase in plasma enzyme levels ([@B9], [@B10]). In our study, both the PBMT and placebo limbs presented similarly increased echo intensity for *rectus femoris* and *vastus lateralis* muscles at 24 and 48 h after the SSC protocol. This is an additional indicative of similar muscle damage between both limbs, showing no positive effect of PBMT. Our initial hypothesis was supported by a previous study ([@B29]) that reported maintenance of echo intensity for the PBMT treated limb while increases were observed only for the placebo limb after an identical study design and SSC protocol. However, our results are contrary to theirs, and although the mechanisms underlying this difference cannot be explained with our methods, this is an indicative that judo athletes and non-athlete physically active people differently respond to PBMT with the intention of muscle damage protection following an SSC protocol. The effectiveness of PBMT to prevent an inflammatory response in judo athletes seems to have no positive response or cannot be detected through echo intensity levels in ultrasonography images.

The muscle damage observed by lower CMJ impulse and higher echo intensity levels is accompanied by a similar increase in muscle soreness 24 and 48 h after the SSC protocol for both PBMT and placebo limbs. Thus, if the muscle damage was attenuated, it was expected that muscle soreness would also reduce. Despite the absence of damage reduction, PBMT can modulate pain through its direct effect on peripheral nerves ([@B23]), which was not observed in our study. Contrary to our findings, a previous study reported positive results for muscle soreness when PBMT was applied before a knee extensor eccentric protocol performed in isokinetic dynamometry ([@B29]). [@B29] observed non-statistical differences between PBMT and placebo limbs after a plyometric protocol equal to ours. However, the authors reported that the PBMT limbs presented up to 30% less muscle soreness than placebo limbs, suggesting clinical relevance despite the absence of statistical significance. Conversely, our findings showed trivial percentage differences between PBMT and placebo treatments at 24 and 48 h after the SSC protocol (0 and 2.8%, respectively). For athletes, a minimal analgesic effect would positively affect performance, however, no effect was observed regarding muscle soreness.

Our findings are contradictory to the recent literature regarding PBMT effects on muscle fatigue ([@B60]) and damage ([@B29]). The different markers of muscle fatigue (CMJ variables and visual analog scale for fatigue) and muscle damage (CMJ impulse, echo intensity, and muscle soreness) showed similar behavior following the SSC protocol, which differed from [@B29] who showed dissociated results for echo intensity and strength production. The mechanisms underlying these differences cannot be explained by our methods, thus further studies should focus on understanding how and why different populations (e.g., according to training level, age, and illness), different muscle groups (e.g., lower or upper limbs), methods of fatigue and damage induction (e.g., jumping, running, and eccentric based protocols), assessment of fatigue and damage markers (e.g., CMJ, and dynamic or isometric peak torque or rate of force development), and different PBMT parameters are differently affected by PBMT.

Our study has both strengths and limitations. The use of a randomized, triple-blind, placebo-controlled trial design, where each evaluator performed the same tests throughout data collection, gave our study internal validity and reduced evaluator bias. The sample size allowed enough power (β \> 0.8) to avoid any type II statistical error. In addition, the use of PBMT and placebo applied in the contralateral limb evaluated on the same day avoided within-subject between-day performance variability and a repeated bout effect that would hide possible positive effects. However, our design did not include biochemical muscle damage blood marker monitoring (e.g., CK). In addition, a wide variety of PBMT parameters have been used to reduce muscle fatigue and damage; therefore, it is unclear if this result would be the same using different parameters to those adopted in our study. Thus, future studies should focus on understanding the ideal PBMT parameters for athletes in order to attenuate fatigue and improve recovery, avoiding sports-related disorders (e.g., overtraining and muscle injuries).

Conclusion {#S5}
==========

Our findings suggest no effects of PBMT applied before exercise to reduce lower limb muscle fatigue assessed by CMJ impulse, peak power output, peak velocity, peak force, and perception of fatigue during an SSC protocol (10 sets of 10 CMJ) for judo athletes. Additionally, no effects of PBMT to attenuate muscle damage markers (i.e., CMJ impulse, echo intensity, and muscle soreness) were observed following the damaging protocol adopted. Thus, judo athletes did not benefit from PBMT (with the respective parameters) applied before exercise to attenuate fatigue and muscle damage symptoms during and following our SSC protocol.
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